No survival benefit from the inhibition of renin-angiotensin system in biliary tract cancer

Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Naminatsu Takahara, Kei Saito, Tsuyoshi Takeda, Gyotane Umefune, Tomotaka Saito, Kaoru Takagi, Takeo Watanabe, Tsuyoshi Hamada, Rie Uchino, Suguru Mizuno, Keisuke Yamamoto, Hirofumi Kogure, Saburo Matsubara, Natsuyo Yamamoto, Hideaki Ijichi, Keisuke Tateishi, Minoru TadaKazuhiko Koike

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Aim: The renin-angiotensin system (RAS) was investigated as a target for cancer treatment. Patients and Methods: A total of 287 patients with biliary tract cancer (BTC) receiving chemotherapy were retrospectively studied to evaluate the role of inhibition of RAS by angiotensin system inhibitors (ASIs). Progression-free survival (PFS) and overall survival (OS) were compared between 74 patients with hypertension, on ASIs (ASI group), 50 patients with hypertension not on ASIs (non-ASI with HT group) and 163 patients without hypertension (non-HT group). Interactions between the use of ASIs and various subgroups were explored. Results: The median PFS was 3.6, 3.9 and 4.6 months (p=0.495) and the median OS was 11.6, 10.9 and 13.1 months (p=0.668), respectively. The use of ASIs was not associated with OS (hazard ratio 1.00, p=0.975) and no subgroups with better survival were identified. Conclusion: No survival benefit from ASIs was observed in BTC.

Original languageEnglish
Pages (from-to)4965-4970
Number of pages6
JournalAnticancer Research
Issue number9
Publication statusPublished - Sept 2016
Externally publishedYes


  • Angiotensin system inhibitor
  • Biliary tract cancer
  • Chemotherapy
  • Renin-angiotensin system


Dive into the research topics of 'No survival benefit from the inhibition of renin-angiotensin system in biliary tract cancer'. Together they form a unique fingerprint.

Cite this